Therapeutic treatment of skin disease with recombinant commensal skin microorganisms
AssigneeAzitra Inc
InventorsAzim Momin Munivar, Travis Michael Whitfill
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
Claims17
A pharmaceutical composition for treating an abnormal skin condition in a human in need thereof, comprising (a) a cell culture composition comprising a bacterial strain selected from Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc, or Oenococcus, and mixtures thereof, wherein the cell culture composition is a living cell culture composition, and wherein the cell culture composition comprises at least one engineered bacterial strain that produces a therapeutically effective amount of a recombinant polypeptide for treating the abnormal skin condition and (b) a pharmaceutically acceptable carrier.
A composition according to 1, wherein the composition comprises an engineered strain of Staphylococcus epidermidis.
A pharmaceutical composition for treating an abnormal skin condition in a human in need thereof, comprising (I) a cell culture composition comprising a bacterial strain selected from Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc, or Oenococcus, and mixtures thereof, wherein the cell culture composition is a living cell culture composition, and wherein the cell culture composition comprises at least one engineered bacterial strain that produces a therapeutically effective amount of a recombinant polypeptide comprising (a) a filaggrin amino acid sequence, (b) a secretion signal, and (c) a cell penetrating peptide and (II) a pharmaceutically acceptable carrier, for treating the abnormal skin condition.
A pharmaceutical composition according to 6, wherein the cell culture composition comprises Staphylococcus epidermidis.
Dependencies are inferred from the claim text.